CRISPR-Cas9 gene editing technology can be used to treat thalassemia
- Why are vegetarians more likely to suffer from depression than meat eaters?
- Small wireless device implanted between skin and skull helps kill cancer cells
- Will the mRNA vaccine that can cure cancer come out near soon?
- Allogeneic T-cell therapy set for landmark first approval
- Boston University denies that the new COVID strain they made has 80% fatality rate
- A new generation of virus-free CAR-T cell therapy
CRISPR-Cas9 gene editing technology can be used to treat thalassemia
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Where do the bacteria in the human gut come from?
CRISPR-Cas9 gene editing technology can be used to treat thalassemia. CRISPR/Cas9 gene editing technology is considered to be one of the most promising strategies for the treatment of various single-gene inherited diseases.
In a study recently published in the journal Molecular Therapy, Professor Alessia Finotti from the University of Ferrara, Italy, and others corrected the β039 thalassemia mutation for the first time through CRISPR/Cas9 gene editing technology.
The results proved that normal β-globin can be obtained after CRISPR/Cas9 correction of erythroid precursor cells from homozygous β039 thalassemia patients. Allele-specific PCR and sequencing proved this.
In addition, the corrected β-globin mRNA accumulation and related β-globin and adult hemoglobin (HbA) can also be successfully produced. This result provides a new idea for the treatment of thalassemia.
First, the author introduced the strategy of using CRISPR/Cas9 gene editing technology to treat patients with thalassemia.
First, the author extracted red blood cell precursor cells with mutation characteristics from patients, and cultured them in vitro for 7 days in a medium without erythropoietin (EPO).
EPO is then added to the culture medium to stimulate cell differentiation and hemoglobin production.
After 3 days, the cells were transfected with the CRISPR-Cas9 module and cultured for another 5 days. In this process, the cell’s genome, transcriptome and protein levels are detected by various means.
(Figure 1, CRISPR-Cas9 gene editing repair process and target gene sequence)
Genome-level testing results show that CRISPR-Cas9 can efficiently correct mutations in related genes in thalassemia patients.
Specifically, the β39 mutant nucleotide is thymine (T), which was successfully converted to normal cytosine (C) after editing.
The results of abundance analysis showed that after CRISPR-Cas9 transfection, the mutation sites in at least 4.5% of the cells were corrected.
Furthermore, the author tested the corrected mRNA expression level. The RT-PCR test results showed that the corrected mRNA expression level was at least about 8 times higher than the original mutant mRNA in the untreated group.
In the end, the author verified that the gene-edited cells can produce the correct β-globin through WB and HPLC technology, indicating that its function can be restored, and the expression of HbA protein has also been significantly restored.
Based on the above results, the authors believe that CRISPR-Cas9 technology has great potential for the treatment of thalassemia caused by nucleotide mutations.
CRISPR-Cas9 gene editing technology can be used to treat thalassemia
(source:internet, reference only)
Disclaimer of medicaltrend.org
